R eceptor-targeted clinical imaging is currently only performed using radionuclide-based techniques, such as positron emission tomography 1 . Magnetic resonance imaging (MRI) using paramagnetic labels has shown potential for receptor imaging of, for example, folic acid 2 , transferrin 3 , HER2/neu 4 and, recently, prostatespecific membrane antigen (PSMA) [5] [6] [7] . However, the clinical translation of these probes has proved elusive. Instead, a non-metallic, non-radioactive and biodegradable particle conjugated with a lowmolecular-weight affinity agent is less likely to elicit an immune response than, for instance, an anti-PSMA antibody 8 . These constrains should provide a stimulus for nanotechnology approaches to become more commonly used in clinical settings. Here, we report the design of a biodegradable MRI agent based on dextran (a nanoscale branched macromolecule) conjugated with a low-molecular-weight, urea-based ligand ( Fig. 1a ) for targeting and imaging of PSMA, an enzyme that is overexpressed on prostate cancer cells and within the tumour neovasculature, and whose expression is limited to only a few normal tissues. Instead of using chemical or metallic labelling, we applied radiofrequency (RF)-based magnetic labelling of dextran hydroxyl protons ( Fig. 1b , also see Supplementary Fig. 1 for molecular-weight-dependent chemical exchange saturation transfer (CEST; a sensitivity-enhancement approach) signals of dextrans and Supplementary Fig. 2 for saturation parameter-dependent CEST signals of dextrans), which can be achieved non-invasively in situ. For magnetic labelling, we used RF saturation, which was subsequently transferred to the water using CEST MRI 9-12 ( Fig. 1c ). CEST MRI enabled the detection of micromolar concentrations of urea-10 kD dextran (Dex10) constructs in vivo by imaging changes in the water signal (that is, changes in the proton concentration of ~1.1 M).
R eceptor-targeted clinical imaging is currently only performed using radionuclide-based techniques, such as positron emission tomography 1 . Magnetic resonance imaging (MRI) using paramagnetic labels has shown potential for receptor imaging of, for example, folic acid 2 , transferrin 3 , HER2/neu 4 and, recently, prostatespecific membrane antigen (PSMA) [5] [6] [7] . However, the clinical translation of these probes has proved elusive. Instead, a non-metallic, non-radioactive and biodegradable particle conjugated with a lowmolecular-weight affinity agent is less likely to elicit an immune response than, for instance, an anti-PSMA antibody 8 . These constrains should provide a stimulus for nanotechnology approaches to become more commonly used in clinical settings. Here, we report the design of a biodegradable MRI agent based on dextran (a nanoscale branched macromolecule) conjugated with a low-molecular-weight, urea-based ligand (Fig. 1a ) for targeting and imaging of PSMA, an enzyme that is overexpressed on prostate cancer cells and within the tumour neovasculature, and whose expression is limited to only a few normal tissues. Instead of using chemical or metallic labelling, we applied radiofrequency (RF)-based magnetic labelling of dextran hydroxyl protons ( Fig. 1b , also see Supplementary Fig. 1 for molecular-weight-dependent chemical exchange saturation transfer (CEST; a sensitivity-enhancement approach) signals of dextrans and Supplementary Fig. 2 for saturation parameter-dependent CEST signals of dextrans), which can be achieved non-invasively in situ. For magnetic labelling, we used RF saturation, which was subsequently transferred to the water using CEST MRI [9] [10] [11] [12] (Fig. 1c ). CEST MRI enabled the detection of micromolar concentrations of urea-10 kD dextran (Dex10) constructs in vivo by imaging changes in the water signal (that is, changes in the proton concentration of ~1.1 M).
Results
To achieve a low background signal and an increased target-tobackground ratio, we chose Dex10, which has a hydrodynamic diameter of 4-6 nm (ref. 13 ) and can easily penetrate tumours, but is quickly washed out from the extracellular space within 30 min (ref. 14 ) . In comparison, dextran of higher molecular weights would accumulate for a longer period of time in the extravascular space of the tumours, making it difficult to detect specific binding. We synthesized PSMA-targeted CEST MRI agents by conjugating Dex10 with a low-molecular-weight, urea-based PSMA-targeting ligand (molecular mass, ~400 g mol -1 ) according to the scheme in Fig. 2a . The binding affinity to PSMA (PSMA inhibitory activity) of the conjugated materials was measured using a standard fluorescencebased assay that tests the inhibitory ability of a compound with respect to the hydrolysis of N-acetylaspartylglutamate (NAAG) to glutamate by the lysates of PSMA-positive (PSMA + ) human prostate adenocarcinoma (LNCaP) cells 6, 15 . Compared with the nonconjugated amino-Dex10 (compound 1; Fig. 2a ), which showed no binding affinity (K i > 1 μ M) to PSMA, the conjugated material urea-Dex10 (compound 3; Fig. 2a ) exhibited a much higher binding affinity, with a K i = 2 nM (half-maximum inhibitory concentration (IC 50 ) = 10 nM; Fig. 2b ). Figure 3a ,b compares the CEST MRI characteristics of urea-Dex10 and the parent compound Dex10. CEST effects are visualized using so-called Z-spectra, in which the reduction of the normalized water signal intensity (S/S 0 ) is displayed as a function of RF saturation frequency offset (Δ ω) relative to the water protons, where S is the MRI signal in the presence of a saturation RF pulse and S 0 is the MRI signal in the absence of a saturation RF pulse. The frequency of protons in the water is set to 0 ppm by convention, and the water signal disappears upon direct saturation at that frequency. The dextran hydroxyl proton saturation transfer to water becomes visible through a slight asymmetry over the 0-2 ppm offset range ( Fig. 3a , also see Supplementary Table 1 for the simulated B 0 -dependent offset to achieve the maximum contrast, where B 0 is the main magneticfield strength), which can be better visualized by performing an A dextran-based probe for the targeted magnetic resonance imaging of tumours expressing prostate-specific membrane antigen Guanshu Liu 1,2 *, Sangeeta Ray Banerjee 1 , Xing Yang 3 , Nirbhay Yadav 1,2 , Ala Lisok 1 , Anna Jablonska 1 , Jiadi Xu 1,2 , Yuguo Li 1,2 , Martin G. Pomper 1 and Peter van Zijl 1,2 * Safe imaging agents that are able to render the expression and distribution of cancer receptors, enzymes or other biomarkers would facilitate clinical screening of the disease. Here, we show that diamagnetic dextran particles that are coordinated to a urea-based targeting ligand for prostate-specific membrane antigen (PSMA) enable targeted magnetic resonance imaging (MRI) of the PSMA receptor. In a xenograft model of prostate cancer, micromolar concentrations of the dextran-ligand probe provided sufficient signal to specifically detect PSMA-expressing tumours via chemical exchange saturation transfer MRI. The dextran-based probe could be detected via the contrast that originated from dextran hydroxyl protons, thereby avoiding the need of chemical substitution for radioactive or metallic labelling. Because dextrans are currently used clinically, dextran-based contrast agents may help to extend receptor-targeted imaging to clinical MRI.
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NATuRe BIoMedIcAl eNgINeeRINg analysis of the so-called magnetization transfer ratio asymmetry, MTR asym = (S -Δω -S +Δω )/S 0 , with respect to the water signal at 0 ppm (Fig. 3b ). The results in this figure show that conjugation to the PSMA-targeting ligand does not appreciably affect the dextran CEST MRI contrast, which is expected because the particle contains only 2.5 mmol mol -1 of free amino group (see Methods). Like Dex10, urea-Dex10 can also be readily detected by CEST MRI, namely, 18 µ M and 20 µ M for generating a 1% MRI signal change at pH 7.4 and 37 o C for Dex10 and urea-Dex10, respectively. As shown in Fig. 3c,d , the pH dependencies are also comparable. These in vitro results demonstrate that conjugation with a PSMA-targeting ligand has a minimal effect on the CEST signal detection properties of dextran.
We then injected PSMA-targeted urea-Dex10 in mice bearing isogenic human prostate cancer PSMA + PC3-PIP and PSMA-negative 
NATuRe BIoMedIcAl eNgINeeRINg (PSMA -) PC3-flu tumours, and assessed changes in the dynamic CEST MRI signal in both tumours. This animal model has been previously validated for testing the PSMA-targeting ability of molecular imaging agents 6, [16] [17] [18] . As shown in Fig. 4 , CEST MRI was able to detect the dynamics of tumour uptake of dextran after urea-Dex10 was administered intravenously at a dose of 375 mg per kg. A substantial increase of > 1% in MTR asym in the mean CEST contrast in both tumour types, that is, 1.28 ± 0.16% and 1.23 ± 0.11% (mean ± s.e.m.) in MTR asym for PC3-PIP and PC3-flu tumours, respectively, could be readily detected at 15 min post-injection ( Fig. 4a,b ). The increase in CEST contrast was as high as 3% in some regions, presumably within the areas in the vicinity of large tumour vessels ( Fig. 4a ). However, after 30 min post-injection, there was a decay of CEST contrast in PSMA -PC3-flu tumours but not in PSMA + PC3-PIP tumours, indicating urea-Dex10 retention in the PSMA + tumour due to the presence of PSMA on the tumour cell surface. At 60 min post-injection, the CEST enhancement by urea-Dex10 in the PC3-PIP tumours was more than twice that in the PC3-flu tumours: 1.33 ± 0.16% versus 0.53 ± 0.11% (mean ± s.e.m.) respectively, indicating specificity to PSMA-expressing tumours. The elevated dextran CEST MRI signal in the PSMA-expressing tumours but not in the PSMAtumours was subsequently confirmed in all mice (n = 5), as shown in the two panels in Fig. 4c , where the CEST signals before and after (60 min) infusion and the difference signals are plotted for both tumour types. To confirm that this higher retention of urea-Dex10 in the PSMA + tumours was caused by the specific binding of dextran particles to PSMA, we also injected non-targeted native dextran particles of the same size, Dex10, to another group of animals (see Supplementary Fig. 6 for the CEST plots), showing that the contrast enhancement of Dex10 in PSMA + tumours was much weaker than that of urea-Dex10. The column scatter plots in Fig. 4d show significant differences between the PSMA + and PSMAtumours injected with urea-Dex10 (n = 5, P = 0.018, Student's t-test, twotailed and unpaired), and between the PSMA + tumours injected with urea-Dex10 and non-targeted Dex10 (n = 3, P = 0.017, Student's t-test, two-tailed and unpaired). Furthermore, pre-treatment with ZJ-43, a commercially available PSMA inhibitor, effectively blocked PSMA and resulted in no observable CEST contrast enhancement in the PSMA + tumours ( Supplementary Fig. 7 ). The signal changes of ~1% (or ~1.1 M in the concentration of protons in water) are of the same order of magnitude as functional MRI signal changes, which are detected routinely with human scanners (> 1.5 T).
To validate these in vivo MRI results, we also prepared urea-Dex10 conjugated with fluorescence dye (IRDye 800CW (LI-COR Biosciences, synthesized according to Supplementary Fig. 3 ) for fluorescence imaging and fluorescence microscopy. Although the in vivo fluorescence images from the same animal model as the MRI experiments ( Fig. 4e ) and biodistribution study using the same fluorescence dye-conjugated urea-Dex10 ( Supplementary Fig. 8 ) are semi-quantitative, they verify the distinctive fluorescence intensities between the PSMA-expressing tumours versus those that do not express PSMA, at 60 min post-injection. The results of the fluorescence microscopy (Fig. 4f ) also confirmed not only a much higher intensity but also a wider distribution for urea-Dex10 in the PSMA + PC3-PIP tumour with respect to the PSMA -PC3-flu tumour. Quantitative analysis of the mean fluorescence intensity ( Fig. 4g ) also showed nearly two-times more dextran particles sequestered within the PSMA + tumour, which is in agreement with the MRI findings. These results confirm the specificity of urea-Dex10 to detect PSMA-expressing prostate tumours.
discussion
PSMA is emerging as the chief biological target for specific imaging of prostate cancer, and is the subject of numerous investigational and clinical studies worldwide using positron emission tomography. Although the urea-based PSMA-targeting ligand forms the basis of a group of emerging clinical radiopharmaceuticals 19 , owing to the need for a high concentration of MRI contrast agent, no similar MRI-based methods with potential for clinical translation are available. Our approach uses biocompatible dextran particles on the order of 20 µ M, which provide a sufficiently sensitive CEST MRI signal to successfully detect PSMA expression in prostate tumours. The sensitivity of the probe has the potential for rapid clinical translation, as dextrans are currently used clinically for other applications at similar glucose concentrations 20 .
CEST contrast by dextran derives from its hydroxyl protons 9, 21 , which are easily accessible and are in rapid exchange with protons of the surrounding water molecules. Similar to glycogen 10 , dextran is a branched polysaccharide, and the CEST MRI detectability of dextran at a particular size is proportional to its number of glucose units. Dextran of higher molecular weight has higher CEST sensitivity on a per-dextran-unit basis, but detectability on a per-glucoseunit basis is similar to those of low-molecular-weight dextrans (see Supplementary Fig. 1 and Supplementary Information) and glucose 11, 12 . It may at first seem best to use a larger particle for higher per-concentration sensitivity, but it is more difficult for larger particles to penetrate tumours, which could increase the background signal and decrease the target-to-background ratio 22 .
Our approach has several important advantages. First, because it involves clinically compatible agents, it is a safe and translatable MRI-labelling method for receptor-specific imaging. Several types of dextrans are currently used clinically and have a proven safety profile 20 . Similar to all other intravenously administered colloids, dextrans can induce anaphylactoid or anaphylactic reactions through two pathomechanisms: the milder reactions are predominantly anaphylactoid and non-antibody-dependent, and the severe reactions are anaphylactic and only occur in patients with high titres of dextran-reactive antibodies, predominantly IgG (but not IgE), mast cells and histamine 23, 24 . The severe dextran-induced anaphylactoid/anaphylactic reaction can be substantially reduced by dextran 1, 
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NATuRe BIoMedIcAl eNgINeeRINg making dextran at least as safe as albumin and starches 25, 26 . Although we demonstrated receptor binding using dextran as the CEST probe, this approach can be tailored to other clinically available polymers and particles, such as polysaccharides, polypeptides and proteins. Indeed, sugar polymers are becoming increasingly important for use in the delivery of drugs, including genetic material 27, 28 , and as molecular tools in cell imaging and in the implementation of vaccines. Second, because the dextran probes do not contain paramagnetic metals, and because clinical-grade dextrans are non-immunogenic 29 , the probes can be potentially used repeatedly without fear of accumulation and toxicity. Third, dextran can also be functionalized to carry drugs such as doxorubicin 30 and methotrexate 31, 32 , and such theranostic constructs could be used to detect the therapeutic agents. Fourth, dextran is available in a range of particle sizes, which enables the design of CEST MRI probes for specific applications. Overall, the approach may extend receptor-targeted and other protein-targeted imaging to clinical MRI. Although we have developed the dextran probes primarily for improving the diagnosis and treatment of prostate cancer, the approach may also be applied to whole-body screening, as PSMA is also overexpressed in the neovasculature of nearly all non-prostate solid tumours 33 . However, this will require the availability of fast CEST sequences (which are currently under development [34] [35] [36] ) to keep the clinical examination brief.
Methods
Chemicals and synthetic chemistry. Amino-dextran (molecular mass = 10 kD) was purchased from LifeTechnologies. The material contains 2.5 mmol mol -1 free amino groups for functionalization. N-hydroxysuccinimide-activated ligand (94 mg, 0.2 mmol), which was synthesized from protected glutamic acid and lysine via a 7-step synthesis 37 , was dissolved in 10 ml water. Dextran (compound 1, Fig. 3 ) 160 mg (0.016 mmol with 0.04 mmol amino groups) and triethylamine 0.5 ml (excess) were then added to the solution. The reaction was kept at room temperature for 5 h. The mixture was loaded to the centrifugal filter units with a cut-off size of 3 kD for purification. After washing five times with 30 ml water, 160 mg of compound 3 was obtained after lyophilization as a white and plastic-like solid. The yield was estimated to be 85% by the weight of product. The conjugation was confirmed by 1 H-NMR spectra ( Supplementary Fig. 4 ). The mean size (z-average) and size heterogeneity (polydispersity index) of the synthesized urea-Dex10 was measured in PBS at room temperature by dynamic light scattering using a Nanosizer ZS90 (Malvern Instruments). The stability of urea-Dex10 at room temperature in PBS was assessed using 1 H-NMR for 1 week.
Receptor-binding assay. PSMA inhibitory activities of compunds 1-3 were determined using a fluorescence-based assay according to a previously reported procedure 17 . Briefly, 25 μ l lysates of PSMA + LNCaP cells were incubated with the inhibitor (12.5 μ l) in the presence of 4 μ M NAAG (12.5 μ l) for 120 min. The amount of glutamate released from NAAG hydrolysis was measured by incubating with a working solution (50 μ l) of the Amplex Red Glutamic Acid Kit (Molecular Probes Inc.) for 60 min. Fluorescence was measured with a VICTOR3V multilabel plate reader (Perkin Elmer Inc.) with excitation at 530 nm and emission at 560 nm. Inhibition curves were determined using semi-log plots, and IC 50 values were 
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NATuRe BIoMedIcAl eNgINeeRINg determined at the concentration at which enzyme activity was inhibited by 50%. Assays were performed in triplicate. Enzyme inhibitory constants (K i values) were generated using the Cheng-Prusoff conversion 38 . Data analysis was performed using GraphPad Prism version 4.00 for Windows (GraphPad Software).
Animals.
All animal experiments were performed in accordance with protocols approved by our institutional Animal Care and Use Committee. PC3-PIP cells, which have 5 ⨯ 10 6 PSMA receptors per cell, were used to generate the xenografts. Isogenic PSMA -PC3-flu cells were used as a negative control 37 . Both cells were gifts from W. Heston (Cleveland Clinic, OH, USA), which were identified by short tandem repeat analysis, and confirmed no mycoplasma contamination. NOD/ SCID mice (6-8-week-old males, Charles River Laboratories, Wilmington, MA, USA) were implanted subcutaneously with PSMA + PC3-PIP and PSMA − PC3-flu cells (2 ⨯ 10 6 in 100 µ l of Matrigel) at the low right and left flanks, respectively. Mice were imaged when the xenografts reached 5-10 mm in diameter. In all the animal experiments, mice were randomly selected for different groups. The investigators were not blinded to the mice in the different groups.
MRI studies. The in vitro CEST contrast of Dex10 and urea-Dex10 were assessed using a vertical bore Bruker 11.7 T MRI scanner equipped with a 15 mm volume coil, as described previously 39, 40 . In vivo MRI studies were carried out on a Biospec 11.7 T horizontal bore MRI scanner equipped with a 23 mm mouse brain volume coil. CEST magnetic resonance images were acquired before and within the first hour after the tail-vein injection of urea-Dex10 particles at a dose of 375 mg per kg (100 µ l of 75 mg ml -1 saline solution) through the tail vein. For the dynamic study, CEST images were repetitively acquired at the offsets of ± 0.6, ± 0.8, ± 1.0 and ± 1.2 ppm. A fat-suppressed rapid acquisition with relaxation enhancement (RARE) sequence with a continuous-wave pre-saturation pulse of B 1 = 1.8 µ T at 3 s (repetition time/echo time (TR/TE) = 5,000/5 ms, RARE factor = 10) was used.
To correct the B 0 inhomogeneity, two water saturation shift referencing (WASSR) scans were acquired before and after the CEST acquisitions. Data were processed using custom-written MATLAB scripts. After correcting for B 0 inhomogeneity using the WASSR method 41 , the in vivo CEST contrast was quantified by averaging the MTR asym = (S −Δω -S +Δω )/S 0 at 1 ppm. The change in CEST MRI was quantified by ∆ MTR asym (t) = MTR asym (t) -MTR asym (t= 0), where t denotes the time after injection.
Fluorescence microscopy. One hour after the injection of fluorescently labelled urea-Dex10 (IRDye 800CW-conjugated urea-Dex10; see Supplementary  Fig. 5 ), animals were anaesthetized with sodium pentobarbital (50 mg per kg, intraperitoneal), and transcardially perfused with 10 ml 0.9% heparinized saline followed by 10 ml 4% paraformaldehyde in phosphate-buffered saline. After dissection, tumours were post-fixed, cryoprotected with 20% sucrose, frozen in dry ice, and then sliced into 20-μ m-thick sections. Slices were stained with DAPI (Sigma) for the cell nuclei and analysed using a Zeiss microscope for the colocalization of dextran that were labelled with IRDye 800CW (excitation/emission (Ex/Em) = 774/789 nm). The red-fluorescence signal of each image was normalized by the total fluorescence intensity of the corresponding DAPI-staining image.
Immunohistochemistry. PSMA + PC3-PIP and PSMA − PC3-flu tumours from the mice were harvested at 24 h after the MRI studies and fixed in 10% buffered formalin. Tissues were subsequently embedded in paraffin and sectioned at 4 μ m thickness. A standard immunohistochemical protocol was performed to stain the tissue sections with anti-PSMA antibody (1:50 dilution, Clone 3E6, Dako), as described previously 42 .
Statistical analysis. The data were expressed as mean ± s.d. and comparative analyses were carried out via unpaired, two-tailed Student's t-tests where appropriate. Differences were considered significant at P < 0.05. Sample sizes were chosen to ensure adequate power (> 80%, at a significance of 0.05) to detect predicted effect sizes, which were estimated on the basis of either preliminary data or previous experiences with similar experiments. Data followed a normal distribution with similar variance. No exclusion criteria were imposed; thus, all mice were included in the analysis. 
Data exclusions
Describe any data exclusions.
No exclusion criteria were imposed; therefore all mice were included in the analyses.
Replication
Describe whether the experimental findings were reliably reproduced.
All in vitro experiments were performed at least one additional time to ensure reproducibility.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Tumor-carried mice were randomized into groups to avoid bias.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Animal preparation and MRI acquisition/processing were performed by different individuals. After MRI acquisition, the collected data was first blinded and then processed.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Graphpad Prism 4.0 and Matlab 2016b.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
All materials are commercially available.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
We used anti-PSMA antibody (Clone 3E6, Dako, Carpinteria, CA).
